Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

4.66USD
2:18pm EDT
Change (% chg)

$0.07 (+1.53%)
Prev Close
$4.59
Open
$4.60
Day's High
$4.68
Day's Low
$4.34
Volume
14,796
Avg. Vol
4,559
52-wk High
$11.10
52-wk Low
$4.08

Latest Key Developments (Source: Significant Developments)

GTX reports Q1 net loss per share of $0.39
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - GTX Inc :GTX provides corporate update and reports first quarter 2017 financial results.Qtrly net loss per share $0.39.GTX Inc- expects to report topline results from its phase 2 clinical trial of enobosarm to treat stress urinary incontinence in Q3 of 2017.As of March 31, 2017, cash and short-term investments were $16.5 million compared to $21.9 million at December 31, 2016.Research and development expenses for quarter ended March 31, 2017 were $4.2 million compared to $4.0 million for same period of 2016.  Full Article

Gtx Inc qtrly loss per share $0.44
Wednesday, 15 Mar 2017 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports fourth quarter and year-end 2016 financial results . Gtx inc -expects to report preliminary results from its phase 2 clinical trial of enobosarm to treat stress urinary incontinence (sui) in q3 of 2017 . Gtx -xpects to begin an initial clinical study of selective androgen receptor degrader in men with castration-resistant prostate cancer in second half of 2017 . Gtx inc- as of december 31, 2016, cash and short-term investments were $21.9 million compared to $29.3 million at december 31, 2015 .Gtx inc qtrly loss per share $0.44.  Full Article

GTx says primary efficacy endpoint met in Enobosarm 9 mg cohort
Thursday, 8 Dec 2016 07:00am EST 

GTx Inc : Primary efficacy endpoint met in Enobosarm 9 mg cohort . Enobosarm 9 mg appears to be safe and generally well tolerated . Plans to report top-line clinical results following completion of clinical trial, which is anticipated to occur in mid-2017 . Trial will continue as planned with a daily dose of either Enobosarm 9 mg or 18 mg .GTx reports results from ongoing Enobosarm phase 2 clinical trial in er+/ar+ breast cancer.  Full Article

GTx achieves second stage 1 milestone in Phase 2 clinical trial
Wednesday, 16 Nov 2016 07:00am EST 

GTx Inc : Top line data from stage 1 of 9 mg cohort expected in December 2016 .GTx achieves second stage 1 milestone in phase 2 clinical trial of enobosarm in ER+/AR+ breast cancer.  Full Article

GTX qtrly loss per share $0.04
Tuesday, 9 Aug 2016 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports second quarter 2016 financial results .Qtrly loss per share $0.04.  Full Article

GTx reports Q1 earnings per share $0.01
Tuesday, 10 May 2016 07:00am EDT 

GTx Inc : GTx provides corporate update and reports first quarter 2016 financial results . Qtrly earnings per share $0.01 .Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.  Full Article

GTx, Inc receives FDA clearance to initiate clinical trial in Stress Urinary Incontinence
Tuesday, 13 Oct 2015 07:00am EDT 

GTx, Inc:Receives FDA clearance to initiate clinical trial in stress urinary incontinence.Says trial to evaluate an orally administered sarm in postmenopausal women with stress urinary incontinence.Says preclinical data demonstrates a sarm can increase pelvic floor muscle mass and potentially improve outcomes in women with sui.Says company plans to initiate the trial by the first quarter of 2016 and anticipates top-line data later in 2016.Says FDA has accepted the company's investigational new drug (ind) application for a phase 2 clinical trial.  Full Article

More From Around the Web

BRIEF-GTX reports Q1 net loss per share of $0.39

* GTX provides corporate update and reports first quarter 2017 financial results